A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Journal of Clinical Lipidology
Familial dysbetalipoproteinemia (FD) is the second most common monogenic lipid disorder (prevalence 1 in 850-3500), characterized by postprandial remnant accumulation and associated with increased cardiovascular disease (CVD) risk. Many FD patients do not achieve non-HDL-C treatment goals, indicating the need for additional lipid-lowering treatment options. To evaluate the effect of the PCSK9 monoclonal antibody evolocumab added to standard lipid-lowering therapy on fasting and post fat loaddoi:10.1016/j.jacl.2022.10.006 pmid:36384662 fatcat:4y6bpcwaurc7jjntgxd4sqyk7i